#United States #New York #Microtech #Medinol #Atrial Microsensor

Microtech's Groundbreaking Atrial Microsensor Implantation in the U.S.

Microtech, a subsidiary of Medinol, is pioneering a new era in cardiac monitoring with the recent implantation of its atrial-pressure microsensor in the United States. This innovative technology promises to transform how heart conditions are managed by providing real-time data that can improve patient outcomes significantly.

On May 16, 2025, two surgical procedures were successfully performed at the New York-Presbyterian/Columbia University Irving Medical Center. These initial implantations were overseen by Dr. Koji Takeda, the hospital's director of adult heart transplantation. He expressed optimism about the device's potential, which is designed to be small, passive, and capable of receiving and transmitting ultrasonic signals without the need for electronic components or antennas.

The Technology Behind the Atrial Microsensor

The atrial microsensor developed by Microtech stands out due to its unique design. Measuring only a few millimeters, it is engineered to be implanted easily alongside existing medical devices. This capability paves the way for future integrations as the microsensor can transform conventional implants into intelligent therapeutic and diagnostic tools.

In conjunction with the five microsensors already implanted in Israel, the recent U.S. procedures indicate a promising expansion of the technology. Dr. Takeda noted the simplicity of the implantation process, which took just five minutes and required minimal adjustments to the existing surgical protocols involving the DAVG (dual atrioventricular graft).

Enhancing Patient Care

Dr. Nir Uriel, the director of advanced heart failure and heart transplant at NewYork-Presbyterian, emphasized the importance of this technology, stating that "non-invasive monitoring of left and right heart pressures over time will greatly enhance our ability to treat these patients. This shift from symptom-based treatment to parameter-driven care signifies a substantial improvement in patient management."

He also highlighted that the ability to measure cardiac pressures continuously has so far yielded reliable data across all participants in the ongoing study, underscoring the microsensor's accuracy and practicality in clinical settings.

Study Expansion and Future Prospects

The Medinol study, dubbed the Microtech FIH, plans to recruit approximately 15 patients from both the U.S. and Israel, creating a diverse dataset to evaluate the microsensor's effectiveness. Medinol's CEO, Dr. Yoram Richter, expressed his excitement about the progress made in the study, stating, "We are thrilled with the sensor's performance thus far and expect this trend to continue, which will highlight the feasibility, ease of use, and accuracy of this groundbreaking system."

Concurrent to the ongoing studies, Medinol is exploring the integration of microsensors into existing medical devices, a project that holds exciting potential to redefine patient care in cardiac health.

About Medinol

Medinol is at the forefront of innovating how diseases are diagnosed and treated. The company specializes in developing cutting-edge devices for various medical applications while working closely with healthcare professionals to enhance the efficacy and reach of medical technology. By leveraging advanced sensor technology, Medinol aims to provide real-time feedback on patients' physiological parameters and improve medical outcomes significantly.

For further inquiries, please visit Medinol's official website or contact their commercial director, Jeff Roach, via email.